---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-26-000017"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:24:10.114714+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arcutis Q4 2025 revenue $127.5M, first profitable quarter; 2026 guidance raised to $480-495M

## Summary
- Q4 net product revenue $127.5M (+84% YoY, +29% sequential); full year $372.1M (+123% YoY).
- Q4 net income $17.4M ($0.14 diluted EPS) vs net loss of $10.8M in Q4 2024; positive operating cash flow of $26.2M.
- Raised 2026 net product revenue guidance to $480-495M from $455-470M.
- Positive Phase 2 data for ZORYVE cream 0.05% in infants (3-24 months) with atopic dermatitis; sNDA submission expected Q2 2026.
- sNDA accepted for ZORYVE cream 0.3% in plaque psoriasis down to age 2; PDUFA June 29, 2026.

## SEC filing metadata
- accession: 0001787306-26-000017
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730626000017/0001787306-26-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730626000017/arqt-20260225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-26-000017
- JSON: https://secwatch.observer/filing/0001787306-26-000017.json
- Plain text: https://secwatch.observer/filing/0001787306-26-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.